Detalles de la búsqueda
1.
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Cancer
; 127(18): 3413-3421, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34181755
2.
[Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects]. / Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie : Übersicht und Management früher und verzögerter Nebenwirkungen.
Internist (Berl)
; 62(6): 611-619, 2021 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-34032877
3.
[Erratum to: Toxicity after chimeric antigen receptor T-cell therapy]. / Erratum zu: Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie.
Internist (Berl)
; 62(6): 694, 2021 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-34115144
4.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
J Clin Oncol
; 42(14): 1665-1675, 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38358946
5.
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Biol Blood Marrow Transplant
; 19(11): 1632-7, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23850653
6.
Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.
Transfus Med Hemother
; 40(4): 251-7, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24179473
7.
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
Bone Marrow Transplant
; 58(11): 1182-1188, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37543712
8.
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Bone Marrow Transplant
; 57(11): 1664-1670, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35982219
9.
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant
; 57(7): 1072-1078, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35459878
10.
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Lancet Haematol
; 7(5): e381-e394, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171061
11.
The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis.
Front Immunol
; 11: 614976, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569061
12.
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.
Bone Marrow Transplant
; 59(1): 153-155, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932418
13.
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
PLoS One
; 7(8): e42426, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22879978
Resultados
1 -
13
de 13
1
Próxima >
>>